107 related articles for article (PubMed ID: 11170921)
21. [Endocarditis due to Campylobacter jejuni and acquired immunodeficiency syndrome].
Torné Cachot J; Garcés Jarque JM; Miralles Basseda R; García Flores A
Rev Clin Esp; 1989 Feb; 184(2):114-5. PubMed ID: 2756206
[No Abstract] [Full Text] [Related]
22. Antibacterial susceptibility of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
Bishara J; Livne G; Ashkenazi S; Levy I; Pitlik S; Ofir O; Lev B; Samra Z
Isr Med Assoc J; 2005 May; 7(5):298-301. PubMed ID: 15909461
[TBL] [Abstract][Full Text] [Related]
23. Orally administered recombinant metallo-beta-lactamase preserves colonization resistance of piperacillin-tazobactam-treated mice.
Stiefel U; Harmoinen J; Koski P; Kääriäinen S; Wickstrand N; Lindevall K; Pultz NJ; Bonomo RA; Helfand MS; Donskey CJ
Antimicrob Agents Chemother; 2005 Dec; 49(12):5190-1. PubMed ID: 16304203
[No Abstract] [Full Text] [Related]
24. In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae.
Burgess DS; Hall RG
Diagn Microbiol Infect Dis; 2004 May; 49(1):41-6. PubMed ID: 15135499
[TBL] [Abstract][Full Text] [Related]
25. Piperacillin/tazobactam vs ceftazidime in the treatment of neutropenic fever in patients with acute leukemia or following autologous peripheral blood stem cell transplantation: a prospective randomized trial.
Harter C; Schulze B; Goldschmidt H; Benner A; Geiss HK; Hoppe-Tichy T; Ho AD; Egerer G
Bone Marrow Transplant; 2006 Feb; 37(4):373-9. PubMed ID: 16400334
[TBL] [Abstract][Full Text] [Related]
26. Detection of bacterial strains producing sulbactam- or tazobactam-sensitive beta-lactamases by the use of disks containing the inhibitors alone instead of combining them with antibiotics.
Banic S
APMIS; 2006 Jan; 114(1):3-9. PubMed ID: 16499654
[TBL] [Abstract][Full Text] [Related]
27. Persistent Campylobacter jejuni infections in patients infected with the human immunodeficiency virus (HIV).
Perlman DM; Ampel NM; Schifman RB; Cohn DL; Patton CM; Aguirre ML; Wang WL; Blaser MJ
Ann Intern Med; 1988 Apr; 108(4):540-6. PubMed ID: 3348562
[TBL] [Abstract][Full Text] [Related]
28. In vitro evaluation of new beta-lactamase inhibitor: YTR830H and derivatives.
Ishida N; Higashitani F; Hanehara C; Uji T; Inoue M; Mitsuhashi S
J Chemother; 1989 Jul; 1(4 Suppl):88-9. PubMed ID: 16312318
[No Abstract] [Full Text] [Related]
29. [Campylobacter jejuni bacteremia in patient with acquired immunodeficiency syndrome and hepatic cirrhosis].
Sánchez-Porto A; Inigo MA; González-Serrano M; Torres-Tortosa M
Med Clin (Barc); 1992 Oct; 99(11):438-9. PubMed ID: 1469949
[No Abstract] [Full Text] [Related]
30. Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanic acid and sulbactam combined with ampicillin and piperacillin against beta-lactamase producing anaerobic bacteria.
Nord CE
J Chemother; 1989 Jul; 1(4 Suppl):273-5. PubMed ID: 16312398
[No Abstract] [Full Text] [Related]
31. Campylobacter fetus subspecies fetus meningitis with chronic alcoholism and diabetes mellitus.
Kato H; Wakasugi H; Mukuta T; Furukawa M; Yokota M; Yamada Y; Funakoshi A; Abe M
Jpn J Med; 1990; 29(5):542-4. PubMed ID: 2089181
[TBL] [Abstract][Full Text] [Related]
32. Evaluating the ototoxicity of topical piperacillin-tazobactam.
Jang CH; Park H; Cho YB; Choi CH
Int J Pediatr Otorhinolaryngol; 2008 Dec; 72(12):1815-21. PubMed ID: 18845345
[TBL] [Abstract][Full Text] [Related]
33. In vitro evaluation of antibiotics for treatment of meningitis caused by Campylobacter fetus subspecies fetus.
Morooka T; Oda T; Shigeoka H
Pediatr Infect Dis J; 1989 Sep; 8(9):653-4. PubMed ID: 2797963
[No Abstract] [Full Text] [Related]
34. Antimicrobial susceptibility of clinical isolates of non-jejuni/coli campylobacters and arcobacters from Belgium.
Vandenberg O; Houf K; Douat N; Vlaes L; Retore P; Butzler JP; Dediste A
J Antimicrob Chemother; 2006 May; 57(5):908-13. PubMed ID: 16533825
[TBL] [Abstract][Full Text] [Related]
35. Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection.
Li C; Kuti JL; Nightingale CH; Mansfield DL; Dana A; Nicolau DP
J Antimicrob Chemother; 2005 Aug; 56(2):388-95. PubMed ID: 16002420
[TBL] [Abstract][Full Text] [Related]
36. Cluster of erythromycin- and ciprofloxacin-resistant Campylobacter jejuni subsp. jejuni from 1999 to 2001 in men who have sex with men, Québec, Canada.
Gaudreau C; Michaud S
Clin Infect Dis; 2003 Jul; 37(1):131-6. PubMed ID: 12830417
[TBL] [Abstract][Full Text] [Related]
37. In-vitro evaluation of "piperacillin and tazobactum" combination in a tertiary-care hospital--a preliminary study.
Kumari N; Mohapatra TM; Rai A; Bhattacharya SK
Indian J Pathol Microbiol; 2006 Jan; 49(1):57-8. PubMed ID: 16625981
[No Abstract] [Full Text] [Related]
38. Evaluation of sensitivity of different organisms to cefepime and tazobactum (megapime XP) in comparison to cefepime and ceftazidime.
Pal RB; Pal P; Venkatesh V; Kulkarni KP
J Indian Med Assoc; 2008 Sep; 106(9):605-6, 611. PubMed ID: 19552092
[TBL] [Abstract][Full Text] [Related]
39. Antimicrobial resistance in gram-positive bacteria.
Rice LB
Am J Med; 2006 Jun; 119(6 Suppl 1):S11-9; discussion S62-70. PubMed ID: 16735146
[TBL] [Abstract][Full Text] [Related]
40. [Antimicrobial susceptibilities of Campylobacter sp strains isolated from humans in 2005 to 2006 in Bielsko-Biala Region, Poland].
Wardak S; Szych J; Duda U
Med Dosw Mikrobiol; 2007; 59(1):43-9. PubMed ID: 17601030
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
